FDA approved drugs:
(show all 11)
| # |
|
Drug Name |
Active Ingredient(s) 19
|
Company |
Approval Date |
| 1 |
|
Avastin
19
50
|
BEVACIZUMAB |
Genentech |
July 2009 |
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:
19
Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:
16
1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
19
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
|
| 2 |
|
Campostar
19
50
|
IRINOTECAN HYDROCHLORIDE |
Pharmacia & Upjohn |
June 1996 |
Disease/s that Drug Treats:metastatic colorectal cancer
Indications and Usage:
19
CAMPTOSAR is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin forpatients with metastatic carcinoma of the colon or rectum. (1) Patients with metastatic carcinoma of the colon or rectum whose diseasehas recurred or progressed following initial fluorouracil-based therapy. (1)
DrugBank Targets:
16
1. DNA topoisomerase I, mitochondrial;2. DNA topoisomerase 1
Mechanism of Action:
19
Target: topoisomerase I-DNA complex
Action: inhibitor of repairs to DNA
FDA: Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzymetopoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strandbreaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complexand prevent religation of these single-strand breaks. Current research suggests that thecytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesiswhen replication enzymes interact with the ternary complex formed by topoisomerase I, DNA,and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strandbreaks.
|
| 3 |
|
CEA-Scan
19
|
|
Immunomedics |
April 1996 |
Disease/s that Drug Treats:colorectal cancer
Indications and Usage:
19
DrugBank Targets:
16
1. Carcinoembryonic antigen-related cell adhesion molecule 1
Mechanism of Action:
19
Target: carcinoembryonic antigen (""CEA"")
Action: marks
FDA: -
|
| 4 |
|
Cyramza
19
50
|
RAMUCIRUMAB |
Eli Lilly |
April 2014 |
Disease/s that Drug Treats:gastric cancer
Indications and Usage:
19
CYRAMZA® is a human vascular endothelial growth factor receptor 2antagonist indicated as a single agent or in combination with paclitaxel, for treatmentof advanced gastric or gastro-esophageal junctionadenocarcinoma, with disease progression on or after priorfluoropyrimidine- or platinum-containing chemotherapy. (1.1) in combination with docetaxel, for treatment of metastatic nonsmallcell lung cancer with disease progression on or afterplatinum-based chemotherapy. Patients with EGFR or ALKgenomic tumor aberrations should have disease progression onFDA-approved therapy for these aberrations prior to receivingCYRAMZA. (1.2) in combination with FOLFIRI, for the treatment of metastaticcolorectal cancer with disease progression on or after priortherapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.(1.3)
DrugBank Targets:
-
Mechanism of Action:
19
Target: ligand-stimulated activation of VEGF Receptor 2
Action: inhibitor
FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulatedactivation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of humanendothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
|
| 5 |
|
Eloxatin
19
50
|
OXALIPLATIN |
Sanofi-aventis |
August 2002 |
Disease/s that Drug Treats:Metastatic colon or rectum carcinomas that have recurred or progressed within six months folowing first-line treatment
Indications and Usage:
19
ELOXATIN is a platinum-based drug used in combination with infusional 5-fluorouracil /leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who haveundergone complete resection of the primary tumor. (1) treatment of advanced colorectal cancer. (1)
DrugBank Targets:
16
1. DNA
Mechanism of Action:
19
Target: DNA replication and transcription
Action: inhibitor
FDA: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives viadisplacement of the labile oxalate ligand. Several transient reactive species are formed, includingmonoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both interandintrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions oftwo adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by anintervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription.Cytotoxicity is cell-cycle nonspecific.In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. Incombination with 5-fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activitygreater than either compound alone in several tumor models [HT29 (colon), GR (mammary), andL1210 (leukemia)].
|
| 6 |
|
Erbitux
19
50
|
CETUXIMAB |
Imclone, Bristol-Myers Squibb |
February 2004 |
Disease/s that Drug Treats:Colorectal Cancer
Indications and Usage:
19
Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicatedfor treatment of:Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the headand neck in combination with radiation therapy. (1.1, 14.1) Recurrent locoregional disease or metastatic squamous cell carcinomaof the head and neck in combination with platinum-based therapy with5-FU. (1.1, 14.1) Recurrent or metastatic squamous cell carcinoma of the head and neckprogressing after platinum-based therapy. (1.1, 14.1)Colorectal CancerK-Ras wild-type, EGFR-expressing, metastatic colorectal cancer asdetermined by FDA-approved tests in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory toirinotecan-based chemotherapy, as a single agent in patients who have failed oxaliplatin- andirinotecan-based chemotherapy or who are intolerant to irinotecan.(1.2, 5.7, 12.1, 14.2)Limitation of Use: Erbitux is not indicated for treatment of Ras-mutantcolorectal cancer. (5.7, 14.2)
DrugBank Targets:
16
1. Epidermal growth factor receptor;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
19
Target: binding of epidermal growth factor (EGF) and other ligands to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1)
Action: inhibitor
FDA: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembraneglycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR,HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelialtissues, including the skin and hair follicle. Expression of EGFR is also detected in many humancancers including those of the head and neck, colon, and rectum. Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitivelyinhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforminggrowth factor-alpha. In vitro assays and in vivo animal studies have shown that binding ofcetuximab to the EGFR blocks phosphorylation and activation of receptor-associated kinases,resulting in inhibition of cell growth, induction of apoptosis, and decreased matrixmetalloproteinase and vascular endothelial growth factor production. Signal transduction throughthe EGFR results in activation of wild-type Ras proteins, but in cells with activating Ras somaticmutations, the resulting mutant Ras proteins are continuously active regardless of EGFRregulation.In vitro, cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC) against certainhuman tumor types. In vitro assays and in vivo animal studies have shown that cetuximabinhibits the growth and survival of tumor cells that express the EGFR. No anti-tumor effects ofcetuximab were observed in human tumor xenografts lacking EGFR expression. The addition ofcetuximab to radiation therapy or irinotecan in human tumor xenograft models in mice resultedin an increase in anti-tumor effects compared to radiation therapy or chemotherapy alone.
|
| 7 |
|
Fusilev
19
|
LEVOLEUCOVORIN CALCIUM |
Spectrum Pharmaceuticals |
March of 2008 |
Disease/s that Drug Treats:rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate
Indications and Usage:
19
Fusilev is a folate analog indicated for: Rescue after high-dose methotrexate therapy in osteosarcoma. Diminishing the toxicity and counteracting the effects of impairedmethotrexate elimination and of inadvertent overdosage of folic acidantagonists. Use in combination chemotherapy with 5-fluorouracil in the palliativetreatment of patients with advanced metastatic colorectal cancer.(1)Limitations of UseFusilev is not approved for pernicious anemia and megaloblastic anemias.Improper use may cause a hematologic remission while neurologicmanifestations continue to progress. (1.1)
DrugBank Targets:
16
1. Thymidylate synthase
Mechanism of Action:
19
Target: therapeutic and toxic effects of folic acidantagonists / therapeutic and toxic effects of fluoropyrimidines used in cancer therapy
Action: counteract/enhance
FDA: 12.1.1 Levoleucovorin effects during high-dose methotrexate therapyLevoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not requirereduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of âonecarbonâmoieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acidantagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.12.1.2 Levoleucovorin effects in combination with 5-fluorouracilLevoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to andinhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily convertedto another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylatesynthase and thereby enhances the inhibition of this enzyme.
|
| 8 |
|
Stivarga
19
50
|
REGORAFENIB |
Bayer/ Bayer HealthCare Pharmaceuticals |
February 2013/ September 2012 |
Disease/s that Drug Treats:gastrointestinal stromal tumor/ metastatic colorectal cancer
Indications and Usage:
19
Stivarga is a kinase inhibitor indicated for the treatment of patients with: Metastatic colorectal cancer (CRC) who have been previously treated withfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGFtherapy, and, if KRAS wild type, an anti-EGFR therapy. (1.1) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor(GIST) who have been previously treated with imatinib mesylate andsunitinib malate. (1.2)
DrugBank Targets:
16
1. Proto-oncogene tyrosine-protein kinase receptor Ret;2. Vascular endothelial growth factor receptor 1;3. Vascular endothelial growth factor receptor 2;4. Vascular endothelial growth factor receptor 3;5. Mast/stem cell growth factor receptor Kit;6. Platelet-derived growth factor receptor alpha;7. Platelet-derived growth factor receptor beta;8. Fibroblast growth factor receptor 1;9. Fibroblast growth factor receptor 2;10. Angiopoietin-1 receptor;11. Discoidin domain-containing receptor 2;12. High affinity nerve growth factor receptor;13. Ephrin type-A receptor 2;14. RAF proto-oncogene serine/threonine-protein kinase;15. Serine/threonine-protein kinase B-raf;16. Mitogen-activated protein kinase 11;17. Tyrosine-protein kinase FRK;18. Tyrosine-protein kinase ABL1
Mechanism of Action:
19
Target: RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl kinases
Action: inhibitor
FDA: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normalcellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumormicroenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 andM-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib thathave been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model,and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some forhuman colorectal carcinoma.
|
| 9 |
|
Vectibix
19
50
|
PANITUMUMAB |
Amgen |
September 2006 |
Disease/s that Drug Treats:colorectal cancer
Indications and Usage:
19
Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicatedfor the treatment of wild-type KRAS (exon 2) metastatic colorectal cancer(mCRC) as determined by an FDA-approved test for this use: In combination with FOLFOX for first-line treatment. (1.1, 14.2) As monotherapy following disease progression after prior treatment withfluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.(1.1, 14.1) Limitation of Use: Vectibix is not indicated for the treatment of patientswith RAS-mutant mCRC or for whom RAS mutation status is unknown.(1.1, 2.1, 5.2, 12.1)
DrugBank Targets:
16
1. Epidermal growth factor receptor
Mechanism of Action:
19
Target: EGFR
Action: inhibitor of ligand binding
FDA: The EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases,including EGFR, HER2, HER3, and HER4. EGFR is constitutively expressed in normal epithelial tissues,including the skin and hair follicle. EGFR is overexpressed in certain human cancers, including colon and rectumcancers. Interaction of EGFR with its normal ligands (eg, EGF, transforming growth factor-alpha) leads tophosphorylation and activation of a series of intracellular proteins, which in turn regulate transcription of genesinvolved with cellular growth and survival, motility, and proliferation. KRAS (Kirsten rat sarcoma 2 viraloncogene homologue) and NRAS (Neuroblastoma RAS viral oncogene homologue) are highly related members ofthe RAS oncogene family. Signal transduction through the EGFR can result in activation of the wild-type KRASand NRAS proteins; however, in cells with activating RAS somatic mutations, the RAS-mutant proteins arecontinuously active and appear independent of EGFR regulation.Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the bindingof ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-inducedreceptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth,induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, andinternalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits thegrowth and survival of selected human tumor cell lines expressing EGFR.
|
| 10 |
|
Xeloda
19
50
|
CAPECITABINE |
Roche |
April 1998/ May 2001 |
Disease/s that Drug Treats:breast cancer/ metastatic colorectal cancer
Indications and Usage:
19
XELODA (capecitabine) is a nucleoside metabolic inhibitor withantineoplastic activity indicated for: Adjuv ant Colon Cancer (1.1)- Patients with Dukesâ C colon cancer Metastatic Colorectal Cancer (1.1)- First-line as monotherapy when treatment with fluoropyrimidinetherapy alone is preferred Metastatic Breast Cancer (1.2)- In combination with docetaxel after failure of prior anthracyclinecontainingtherapy- As monotherapy in patients resistant to both paclitaxel and ananthracycline-containing regimen
DrugBank Targets:
16
1. Thymidylate synthase;2. DNA;3. RNA
Mechanism of Action:
19
Target: capecitabine
Action: converted to 5-fluorouracil (5-FU) --> cause cell injury
FDA: Enzymes convert capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cellsmetabolize 5-FU to 5-fluoro-2â-deoxyuridine monophosphate (FdUMP) and 5-fluorouridinetriphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First,FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase(TS) to form a covalently bound ternary complex. This binding inhibits the formation ofthymidylate from 2â-deoxyuridylate. Thymidylate is the necessary precursor of thymidinetriphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compoundcan inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporateFUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic errorcan interfere with RNA processing and protein synthesis.
|
| 11 |
|
Zaltrap
19
50
|
ZIV-AFLIBERCEPT |
Sanofi-aventis |
August 2012 |
Disease/s that Drug Treats:metastatic colorectal cancer
Indications and Usage:
19
ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan- (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC)that is resistant to or has progressed following an oxaliplatin-containingregimen. (1)
DrugBank Targets:
16
1. Vascular endothelial growth factor A;2. Placenta growth factor;3. Vascular endothelial growth factor B
Mechanism of Action:
19
Target: VEGF-A, VEGF-B, PlGF
Action: inhibitor of binding and activation of their cognate receptors
FDA: Ziv-aflibercept acts as a soluble receptor that binds to human VEGF-A (equilibrium dissociationconstant KD of 0.5 pM for VEGF-A165 and 0.36 pM for VEGF-A121), to human VEGF-B (KD of1.92 pM), and to human PlGF (KD of 39 pM for PlGF-2). By binding to these endogenousligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. Thisinhibition can result in decreased neovascularization and decreased vascular permeability.In animals, ziv-aflibercept was shown to inhibit the proliferation of endothelial cells, therebyinhibiting the growth of new blood vessels. Ziv-aflibercept inhibited the growth ofxenotransplanted colon tumors in mice.
|
Drugs for Rectum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 556)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Hydromorphone |
Approved, Illicit |
Phase 4 |
|
466-99-9 |
5284570
|
|
Synonyms:
(-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one
(-)-(5R)-4,5-Epoxy-3-hydroxy-9a-methylmorphinan-6-one
(-)-(5R)-4,5-Epoxy-3-hydroxy-9α-methylmorphinan-6-one
(-)-Hydromorphone
(5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one
18145-12-5
3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one
4,5a-Epoxy-3-hydroxy-17-methyl-6-morphinanone
4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone
4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one
4,5α-epoxy-3-hydroxy-17-methyl-6-morphinanone
41376-02-7
466-99-9
6-Deoxy-7,8-dihydro-6-oxomorphine
7,8-Dihydromorphinone
C07042
CHEBI:5790
CHEMBL398707
CID5284570
D08047
DB00327
DEA No. 9150
Dihydromorfinon
Dihydromorfinon [Czech]
Dihydromorphinone
Dilaudid
Dilaudid Oros
Dilaudid-hp
DiMo
Dimorphone
|
EINECS 207-383-5
Hidromorfona
Hidromorfona [INN-Spanish]
HSDB 3341
Hydromorfona
Hydromorfona [Spanish]
Hydromorphon
hydromorphone
Hydromorphone
Hydromorphone (INN)
Hydromorphone [INN:BAN]
Hydromorphone HCL
Hydromorphone hydrochloride
Hydromorphonum
Hydromorphonum [INN-Latin]
Idromorfone
Idromorfone [DCIT]
Laudacon
Laudicon
LS-187185
LS-92152
MolPort-004-285-951
Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl- (8CI)
Novolaudon
NSC 19046
NSC19046
Palladone
UNII-Q812464R06
WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ JQ P1
|
|
| 2 |
|
Oxycodone |
Approved, Illicit, Investigational |
Phase 4 |
|
76-42-6 |
5284603
|
|
Synonyms:
(-)-14-Hydroxydihydrocodeinone
(-)-Oxycodone
(5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one
124-90-3 (hydrochloride)
14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one
14-Hydroxydihydrocodeinone
25333-72-6 (Terephthalate)
4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5a-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
76-42-6
AC-16043
AC1Q4DTG
BRN 0043446
C08018
CHEBI:7852
CHEMBL656
CID5284603
Combunox
D05312
DB00497
DEA No. 9143
dihydro-14-Hydroxycodeinone
Dihydro-14-hydroxycodeinone
Dihydrohydroxycodeinone
Dihydrohydroxycondeinone
Dihydrone
Dihydroxycodeinone
Dinarkon
Diphydrone
EINECS 200-960-2
Endine (Australia)
Endocet
Endodan
Endone
Eubine
Eubine [France]
Eucodal
Eucodalum
Eukodal
Eutagen
HSDB 3142
Hydroxycodeinon
LS-92148
MolPort-004-285-989
Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI)
NSC 19043
NSC19043
|
Ossicodone
Ossicodone [DCIT]
Oxanest
Oxicodona
Oxicodona [INN-Spanish]
Oxicon
Oxicone
Oxiconum
Oxikon
Oxycodeinon
Oxycodeinone
Oxycodon
oxycodone
Oxycodone
Oxycodone (USAN/INN)
Oxycodone [USAN:INN:BAN]
Oxycodone Concentrate
Oxycodone Hcl
Oxycodone hydrochloride
Oxycodone Hydrochloride
Oxycodonum
Oxycodonum [INN-Latin]
Oxycon
Oxycone
Oxycontin
Oxyfast
OxyFAST
OxyIR
Oxynorm
OxyNorm
Pancodine
Pancodone retard (United Kingdom)
Percobarb
Percodan
Percolone
PTI-821
Purdue frederick brand OF oxycodone
Remoxy
Roxicet
Roxicodone
Supendol
Supendol [Canada]
Supeudol
Tecodin
Tekodin
Tekodin (free base)
Thecodine
Thekodin
Theocodin
UNII-CD35PMG570
WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1
|
|
| 3 |
|
Methadone |
Approved, Illicit |
Phase 4 |
|
76-99-3 |
4095
|
|
Synonyms:
(-)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
(-)-Methadone
(+)-Methadone
(+-)-Methadone
(+/-)-methadone
(+/-)-Methadone
(+/-)-methadone hydrochloride
(+/-)-Methadone hydrochloride
(+/-)-Tussal
(±)-methadone
(6R)-Methadone
(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
(R)-6-(Dimethylamino)-4,4-diphenyl-3-hetpanone
(S)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
1095-90-5 (hydrochloride)
297-88-1
3-14-00-00278 (Beilstein Handbook Reference)
3-14-00-00279 (Beilstein Handbook Reference)
3-Hetpanone, 6-(dimethylamino)-4,4-diphenyl-, (R)- (9CI)
5653-80-5
6-(Dimethylamino)-4,4-diphenyl-3-heptanone dl-mixture
6-(dimethylamino)-4,4-diphenylheptan-3-one
6-dimethylamino-4,4-di(phenyl)heptan-3-one
6-dimethylamino-4,4-Diphenyl-3-heptanone
6-Dimethylamino-4,4-diphenyl-3-heptanone
6S-Methadone
76-99-3
A 4624
AC-16055
AC1L1HEG
AC1Q2RLW
Adanon
Adanon hydrochloride
AddiCare brand OF methadone hydrochloride
Adolan
Algidon
Algolysin
Algovetin
Althose
Althose hydrochloride
Amidon
Amidone
AN 148
AN-148 (*Hydrochloride*)
Biodone
Biomet brand OF methadone hydrochloride
Biscuits
BRN 3213667
BRN 3213668
BRN 3213669
Butalgin
C07163
CHEBI:6807
CHEMBL651
CID4095
D08195
d-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
DB00333
DEA No. 9250
Depridol
Dextromethadone
Diaminon
Diaminon hydrochloride
DivK1c_000963
dl-Methadone
DL-Methadone
DL-Methadone hydrochloride
d-Methadone
Dollies
Dolly
Dolofin hydrochloride
Dolohepton
Dolophin
Dolophin hydrochloride
Dolophine
Dolophine (*Hydrochloride*)
Dolophine HCL
EINECS 200-996-9
Esteve brand OF methadone hydrochloride
Fenadon
Fenadone
Fenadone (*Hydrochloride*)
Generics brand OF methadone hydrochloride
GlaxoSmithKline brand OF methadone hydrochloride
|
Heptadon
Heptadone
Heptadone (*Hydrochloride*)
Heptanon
Heptanon (*Hydrochloride*)
Heptanon (pharmaceutical)
Hoechst 10820
Hoescht 10820 (*Hydrochloride*)
HSDB 3119
Hydrochloride, methadone
IDI1_000963
K 174
KBio1_000963
Ketalgin
Ketalgin hydrochloride
L-(+)-Methadone
L000874
L-6-(Dimethylamino)-4,4-diphenyl-3-heptanone
Levometadona
Levometadona [INN-Spanish]
Levomethadone [INN]
Levomethadonum
Levomethadonum [INN-Latin]
Levothyl
l-Methadone
L-Polamidon
l-Polamivet
LS-74485
LS-74486
LS-74487
Mallinckrodt brand OF methadone hydrochloride
Martindale brand OF methadone hydrochloride
Mecodin
Mephenon
Metadol
Metadona
Metadona [INN-Spanish]
Metadona [Spanish]
Metadone
Metadone [DCIT]
Metasedin
Methaddict
Methadon
Methadona
Methadona [Spanish]
methadone
Methadone
Methadone (BAN)
Methadone [INN:BAN]
Methadone HCL
Methadone HCL Intensol
Methadone hydrochloride
Methadone M
Methadonum
Methadonum [INN-Latin]
Methadonum [Latin]
Methadose
Methaquaione
Methex
Miadone
Moheptan
MolPort-001-785-650
NINDS_000963
Pharmascience brand OF methadone hydrochloride
Phenadone
Phenadone (*Hydrochloride*)
Phenadone hydrochloride
Phymet
Physeptone
Pinadone
Pinewood brand OF methadone hydrochloride
Polamidon
Polamidone
Polamivet
Racemic methadone
Rosemont brand OF methadone hydrochloride
Roxane brand OF methadone hydrochloride
S-(+)-Methadone
Sedo-Rapide
Symoron
Tussol
UNII-UC6VBE7V1Z
Westadone
Yamanouchi brand OF methadone hydrochloride
|
|
| 4 |
|
Guaifenesin |
Approved, Investigational, Vet_approved |
Phase 4,Phase 2,Not Applicable |
|
93-14-1 |
3516
|
|
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
Amonidren
Amonidrin
Aresol
Benylin-e
Breonesin
Bronchol
Ether, guaiacol glyceryl
Glycerin ether
Glycerin guaiacolate
glycero-Guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl ether, guaiacol
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
|
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolate, glycerol
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesina
Guaifenesine
guaiphenesin
Guaiphenesin
Guaiphenesine
Guaiphenezine
Guaiphesin
Guiatuss
Humibid
Hustosil
Hytuss
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
P-Cresyl acetate
Pneumomist
Propanosedyl
Reduton
Robitussin
Scott tussin
Scott-tussin
ScottTussin
|
|
| 5 |
|
Gabapentin |
Approved, Investigational |
Phase 4 |
|
60142-96-3 |
3446
|
|
Synonyms:
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
1-(Aminomethyl)cyclohexaneacetate
1-(Aminomethyl)cyclohexaneacetic acid
1-(Aminomethyl)-cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
Aclonium
AKOS000280865
apo-Gabapentin
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
Convalis
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G0318
G-154
G154_SIGMA
Gabapen
gabapentin
Gabapentin
Gabapentin (JAN/USAN/INN)
gabapentin (Neurontin)
Gabapentin [USAN:INN:BAN]
Gabapentin GR
Gabapentin hexal
Gabapentin Hexal
Gabapentin stada
Gabapentin Stada
gabapentina
Gabapentina
Gabapentine
Gabapentine [INN-French]
gabapentinium
Gabapentino
|
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentin-ratiopharm
Gabapentinum
Gabapentinum [INN-Latin]
Gabapetin
GBN
Go 3450
GOE 2450
Goe-3450
Hexal brand of gabapentin
HMS1570N03
HMS2089J03
HSDB 7364
I06-0677
L000733
Lopac0_000582
Lopac-G-154
LS-7194
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
Neurontin
Neurontin (TN)
novo-Gabapentin
Novo-Gabapentin
novo-Gabapentine
Novopharm brand of gabapentin
NSC742194
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
PMS-Gabapentin
Prestwick_151
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
ratiopharm brand of gabapentin
S2133_Selleck
Serada
SMR000058311
SPBio_002822
Stadapharm brand of gabapentin
STK598009
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
|
|
| 6 |
|
Morphine |
Approved, Investigational |
Phase 4 |
|
57-27-2 |
5288826
|
|
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Anhydrous morphine
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
Chloride, morphine
CID5288826
Contin, MS
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
|
HSDB 2134
Infumorph
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
morfina
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine [BAN]
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine Sulfate
MORPHINE SULFATE
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
Sulfate, morphine
UNII-76I7G6D29C
Unkie
|
|
| 7 |
|
Bupivacaine |
Approved, Investigational |
Phase 4,Not Applicable |
|
38396-39-3, 2180-92-9 |
2474
|
|
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(±)-bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
15233-43-9
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
2180-92-9
38396-39-3
AB00053674
Abbott brand OF bupivacaine hydrochloride
AC1L1DRE
AC1Q5LX4
AC-2096
AH 250
AKOS001637202
Anekain
Anhydrous, bupivacaine
AR-1A0242
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bio-0886
Bloqueina
BPBio1_000298
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bucaine
Bucaine (TN)
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
bupivacaine
Bupivacaine
Bupivacaine (INN)
Bupivacaine [INN:BAN]
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine HCL KIT
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacaine Monohydrochloride, Monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
C07529
C18H28N2O
Carbonate, bupivacaine
Carbostesin
cBupivacaine
CBupivacaine
CHEBI:3215
|
CHEMBL1098
CID2474
D07552
DB00297
DepoBupivacaine
DivK1c_000758
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
Dolanaest
DUR-843
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
Hydrochloride, bupivacaine
IDI1_000758
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MLS001361336
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Pisa brand OF bupivacaine hydrochloride
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SMR000058218
SPBio_001558
SPBio_002489
Spectrum_001524
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
|
|
| 8 |
|
Hydrocodone |
Approved, Illicit, Investigational |
Phase 4 |
|
125-29-1 |
5284569
|
|
Synonyms:
(-)-Dihydrocodeinone
(5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one
1037-91-8
125-29-1
34195-34-1 (tartrate (1:1), hydrate (2:5))
3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one
4,5.alpha.-Epoxy-3-methoxy-17-methylmorphinan-6-one
4,5-a-Epoxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
4,5-α-epoxy-3-methoxy-17-methylmorphinan-6-one
4-27-00-03580 (Beilstein Handbook Reference)
50678-79-0
6-Oxo-3-methoxy-N-methyl-4,5-epoxymorphinan
9007-52-7
Bekadid
BRN 0094193
C08024
CHEBI:5779
CHEMBL1457
CID5284569
Codinovo
D08045
DB00956
DEA No. 9193
Dico
DICO
Dicodid
Dihydrocodeinone
Du pont brand OF hydrocodone tartrate
EINECS 204-733-9
hidrocodona
Hidrocodona
Hidrocodona [INN-Spanish]
HSDB 3097
|
Hycodan
Hycon
Hydrocodeinonebitartrate
Hydrocodon
Hydrocodone
HYDROCODONE
Hydrocodone (INN)
Hydrocodone [INN:BAN]
Hydrocodone bitartrate
Hydrocodone tartrate (1:1), hydrate (2:5)
Hydrocodonum
Hydrocodonum [INN-Latin]
Hydrocon
Hydrocone
Hydroconum
Idrocodone
Idrocodone [Dcit]
Idrocodone [DCIT]
Knoll brand OF hydrocodone tartrate
LS-92156
MolPort-002-527-170
Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl- (8CI)
Morphinan-6-one, 4,5-epoxy-3-methoxy-17-methyl-, (5alpha)- (9CI)
Multacodin
NCGC00159317-02
NCGC00159317-03
Nourypharma brand OF hydrocodone tartrate
NSC 19044
NSC19044
Robidone
Robins brand OF hydrocodone tartrate
STOCK1N-54181
UNII-6YKS4Y3WQ7
WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ JO1 P1
Wyeth brand OF hydrocodone tartrate
|
|
| 9 |
|
Ketorolac |
Approved |
Phase 4 |
|
74103-06-3, 66635-83-4 |
3826
|
|
Synonyms:
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-isomer
(+-)-Ketorolac
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC1L1GSW
AC-545
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
I14-2832
Ketoralac
|
ketorolac
Ketorolac
Kétorolac
Ketorolac (INN)
Ketorolac [INN:BAN]
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
rac-Ketorolac
RS 37619
RS-37619
SBB067312
STL018674
Toradol
Toradol (TN)
UNII-YZI5105V0L
|
|
| 10 |
|
Ketamine |
Approved, Vet_approved |
Phase 4 |
|
6740-88-1 |
3821
|
|
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
| 11 |
|
Orphenadrine |
Approved |
Phase 4 |
|
83-98-7 |
4601
|
|
Synonyms:
2-(phenyl-o-tolylmethoxy)ethyldimethylamine
2-(Phenyl-o-tolylmethoxy)ethyldimethylamine
2-(Phenyl-O-tolylmethoxy)ethyldimethylamine
2-methyldiphenhydramine
2-Methyldiphenhydramine
341-69-5 (hydrochloride)
4-06-00-04727 (Beilstein Handbook Reference)
4682-36-4 (citrate)
83-98-7
AB00053510
AC1L1IJ4
Antiflex
b-Dimethylaminoethyl 2-methylbenzhydryl ether
beta-Dimethylaminoethyl 2-methylbenzhydryl ether
beta-Dimethylaminoethyl-2-methylbenzhydryl ether
Biorphen
BPBio1_000349
BRD-A53576514-003-03-1
BRN 1885151
Brocadisipal
Brocasipal
BSPBio_000317
BSPBio_002141
C07935
CBDivE_006102
CHEBI:177779
CHEBI:7789
CHEMBL900
CID4601
Citrate, norflex orphenadrine
Citrate, orphenadrine
D08305
DB01173
Dimethyl-[2-(phenyl-o-tolyl-methoxy)-ethyl]-amine
Dimethyl-[2-(phenyl-O-tolyl-methoxy)-ethyl]-amine
Disipal
DivK1c_000853
EINECS 201-509-2
HSDB 3139
Hydrochloride, orphenadrine
IDI1_000853
KBio1_000853
KBio2_001525
KBio2_004093
KBio2_006661
KBio3_001641
KBioGR_000880
KBioSS_001525
L001253
Lopac0_000884
LS-68148
Lysantin
Mefenamine
Mefenamine, sodium
Mephenamine
Methyldiphenylhydramine
Mialgin (TN)
Mio-Rel
MolPort-002-052-046
Myolin
Myotrol
N,N-Dimethyl-2-(a-2-tolylbenzoyloxy)ethylamine
N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamin
N,N-dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine
N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamine
|
N,N-Dimethyl-2-(o-methyl-alpha-phenylbenzyl)oxy)ethylamine
N,N-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine
N,N-Dimethyl-2-(phenyl(O-tolyl)methoxy)ethanamine
N,N-Dimethyl-2-(α-2-tolylbenzoyloxy)ethylamine
N,N-Dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine
N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine
N,N-Dimethyl-2-[(o-methyl-alpha-phenylbenzyl)oxy]ethylamine
N,N-Dimethyl-2-[(O-methyl-alpha-phenylbenzyl)oxy]ethylamine
N,N-Dimethyl-2-[(O-methyl-a-phenylbenzyl)oxy]ethylamine
N,N-dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine
N,N-Dimethyl-2-[(O-methyl-α-phenylbenzyl)oxy]ethylamine
N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine
NCGC00015771-09
NCGC00089814-02
NCGC00089814-03
NINDS_000853
Norflex
Norflex orphenadrine citrate
Norflex Orphenadrine Citrate
o-methyldiphenhydramine
o-Methyldiphenhydramine
O-Methyldiphenhydramine
o-monomethyldiphenhydramine
o-Monomethyldiphenhydramine
O-Monomethyldiphenhydramine
Oprea1_476547
Orfenadrina
Orfenadrina [INN-Spanish]
Orfro
ORP
Orphenadine
Orphenadinum
Orphenadrin
orphenadrine
Orphenadrine
Orphenadrine (INN)
Orphenadrine [INN:BAN]
Orphenadrine citrate
Orphenadrine citrate, norflex
Orphenadrine hydrochloride
Orphenadrinum
Orphenadrinum [INN-Latin]
Orphenate
Orphenedrine
phenyl-o-tolylmethyl dimethyaminoethyl ether
Phenyl-o-tolylmethyl dimethyaminoethyl ether
Phenyl-O-tolylmethyl dimethyaminoethyl ether
Prestwick0_000239
Prestwick1_000239
Prestwick2_000239
Prestwick3_000239
Sodium mefenamine
Sodium Mefenamine
SPBio_001255
SPBio_002238
Spectrum_001045
Spectrum2_001038
Spectrum3_000531
Spectrum4_000460
Spectrum5_001036
ST50406606
UNII-AL805O9OG9
WS 2434
β-dimethylaminoethyl 2-methylbenzhydryl ether
|
|
| 12 |
|
Tramadol |
Approved, Investigational |
Phase 4 |
|
27203-92-5 |
33741
|
|
Synonyms:
(+)-(R,R)-trans-Tramadol
(+)-Tramadol
(+)-trans-2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cyclohexanol
(+)-trans-Tramadol free ba
(1R,2R)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol
(1R,2R)-2-[(dimethylamino)methyl]-1-[3-(methyloxy)phenyl]cyclohexanol
(1R,2R)-2-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexanol
1a Brand OF tramadol hydrochloride
27203-92-5
AbZ brand OF tramadol hydrochloride
AC1L1Q6E
AC1Q59O2
Acis brand OF tramadol hydrochloride
Adolonta
AKOS005066335
Aliud brand OF tramadol hydrochloride
Allphar brand OF tramadol hydrochloride
Alpharma brand OF tramadol hydrochloride
Amadol
Amanda
Amanda (TN)
Antigen brand OF tramadol hydrochloride
ASTA medica brand OF tramadol hydrochloride
Azupharma brand OF tramadol hydrochloride
Basics brand OF tramadol hydrochloride
Bayvit brand OF tramadol hydrochloride
Betapharm brand OF tramadol hydrochloride
Bexal brand OF tramadol hydrochloride
BIDD:GT0075
Biocodex brand OF tramadol hydrochloride
Biodalgic
Biokanol
Byk brand OF tramadol hydrochloride
C07153
CHEMBL1066
Christiaens brand OF tramadol hydrochloride
Ciclum brand OF tramadol hydrochloride
CID33741
Cinfa brand OF tramadol hydrochloride
Clonmel brand OF tramadol hydrochloride
Contramal
Crispin
CSL Brand OF tramadol hydrochloride
D08623
DB00193
Docpharm brand OF tramadol hydrochloride
Dolorgiet brand OF tramadol hydrochloride
Edigen brand OF tramadol hydrochloride
EINECS 248-319-6
Elerte brand OF tramadol hydrochloride
Erempharma brand OF tramadol hydrochloride
Expanscience brand OF tramadol hydrochloride
Grunenthal brand OF tramadol hydrochloride
Hameln brand OF tramadol hydrochloride
Heumann brand OF tramadol hydrochloride
Hexal brand OF tramadol hydrochloride
HMS2090D10
Janssen brand OF tramadol hydrochloride
Jsp005295
Juta brand OF tramadol hydrochloride
Jutadol
Kade brand OF tramadol hydrochloride
Kern brand OF tramadol hydrochloride
Knoll brand OF tramadol hydrochloride
Krewel brand OF tramadol hydrochloride
Lakeside brand OF tramadol hydrochloride
Lichtenstein brand OF tramadol hydrochloride
Lindopharm brand OF tramadol hydrochloride
LS-57115
LS-57116
mabo Brand OF tramadol hydrochloride
Medix brand OF tramadol hydrochloride
Merck dura brand OF tramadol hydrochloride
MLS000333190
MolPort-002-507-778
MTW Brand OF tramadol hydrochloride
MTW Tramadol
MTWTramadol
MTW-Tramadol
Mundipharma brand OF tramadol hydrochloride
NCGC00159343-02
Nobligan
Normon brand OF tramadol hydrochloride
ortho Brand OF tramadol hydrochloride
Prontofort
Q Pharm brand OF tramadol hydrochloride
Q-Pharm brand OF tramadol hydrochloride
Ralivia ER
|
Ralivia flashtab
Ralivia Flashtab
Ranitidin 1a pharma
Ratiopharm brand OF tramadol hydrochloride
Rowa brand OF tramadol hydrochloride
Searle brand OF tramadol hydrochloride
SMR000436547
Stadapharm brand OF tramadol hydrochloride
STOCK4S-19075
TAD brand OF tramadol hydrochloride
Takadol
Theradol
Theraplix brand OF tramadol hydrochloride
Tiral
Topalgic
Tradol
Tradol puren
Tradol-puren
TradolPuren
Tradonal
Tradonal odis
Tralgiol
Trama 1a pharma
Trama abz
Trama dorsch
Trama KD
Tramabeta
Tramadin
Tramadoc
tramadol
Tramadol
Tramadol (INN)
Tramadol [INN:BAN]
Tramadol 1a
Tramadol acis
Tramadol al
Tramadol asta medica
Tramadol basics
Tramadol bayvit
Tramadol bexal
Tramadol cinfa
Tramadol dolgit
Tramadol edigen
Tramadol hameln
Tramadol HCl
Tramadol HCl BP/EP
Tramadol heumann
Tramadol hydrochloride
Tramadol kern
Tramadol lichtenstein
Tramadol lindo
Tramadol mabo
Tramadol normon
Tramadol PB
Tramadol ratiopharm
Tramadol stada
Tramadol viatris brand
Tramadol-dolgit
TramadolDolgit
Tramadol-hameln
TramadolHameln
Tramadolor
Tramadolratiopharm
Tramadol-ratiopharm
Tramadolum
Tramadolum [INN-Latin]
Trama-dorsch
TramaDorsch
Tramadura
Tramagetic
Tramagit
Tramake
Tramal
Tramex
Tramodol Hcl
Tramundin
Trasedal
Tridural
Ultram
Ultram ER
UNII-39J1LGJ30J
Viatris brand OF tramadol
Xymel 50
Zambon brand OF tramadol hydrochloride
Zamudol
Zumalgic
Zydol
Zytram
|
|
| 13 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 4,Phase 3,Not Applicable |
|
437-38-7 |
3345
|
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
| 14 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676
|
|
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
Leostesin
|
Lida-Mantle
Lidocaina
Lidocaína
Lidocaina [INN-Spanish]
lidocaine
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
| 15 |
|
Acetaminophen |
Approved |
Phase 4 |
|
103-90-2 |
1983
|
|
Synonyms:
4-(acetylamino)Phenol
4-(Acetylamino)phenol
4-acetamidophenol
4-Acetamidophenol
4-Acetaminophenol
4'-hydroxyacetanilide
4'-Hydroxyacetanilide
4-Hydroxyacetanilide
4-Hydroxyanilid kyseliny octove
A.F. anacin
Abenol
Abensanil
Abrol
Abrolet
AC1Q1KYJ
AC1Q1KYK
Acamol
Accu-tap
Accu-Tap
Acenol
Acephen
Acertol
Aceta elixir
Aceta Elixir
Aceta tablets
Aceta Tablets
Acetaco
Acetagesic
Acetalgin
Acetaminofen
Acetaminofén
Acetaminophen uniserts
Acetaminophene
Acétaminophène
Acetamol
Acetavance
Acetofen
Actamin
Actamin extra
Actamin super
Actifed plus
Actifed Plus
Actimol
Actimol chewable tablets
Actimol children's suspension
Actimol infants' suspension
Actimol junior strength caplets
Actron
Afebrin
Afebryl
Aferadol
Algesidal
Algina
Algomol
Algotropyl
Allay
alpha-Per
Alpiny
Alpinyl
Alvedon
Amadil
Aminofen
Aminofen max
Anacin
Anacin 3
Anacin-3
Anacin-3 extra strength
Anadin dla dzieci
Anaflon
Analter
Anapap
Andox
Anelix
Anexsia
Anexsia 10/660
Anexsia 5/325
Anexsia 7.5/325
Anexsia 7.5/650
Anhiba
Anoquan
Anti-algos
Antidol
Anuphen
Apacet
Apacet capsules
Apacet elixir
Apacet extra strength caplets
Apacet extra strength tablets
Apacet regular strength tablets
Apadon
Apamid
Apamide
APAP
a-Per
A-Per
Apitrelal
apo-Acetaminophen
Arfen
Arthralgen
Asetam
Asomal
Aspac
Aspirin free anacin maximum strength caplets
Aspirin free anacin maximum strength gel caplets
Aspirin free anacin maximum strength tablets
Aspirin-free anacin
Aspirin-free excedrin caplets
Asplin
Atasol
Atasol caplets
Atasol drops
Atasol forte caplets
Atasol forte tablets
Atasol oral solution
Atasol tablets
Atralidon
Babikan
Bacetamol
Bancap
Bancap HC
Banesin
Bayer Select
Bayer select allergy-sinus
Bayer select head cold
Bayer select headache pain
Bayer select maximum strength headache pain relief formula
Bayer select menstrual multi-symptom
Bayer select sinus pain relief
Benmyo
Ben-u-ron
Bickie-mol
Biocetamol
Bucet
Butalbital
Butapap
Cadafen
Calapol
Calmanticold
Calonal
Calpol
Capital
Capital with codeine
Captin
Causalon
CCRIS 3
Cefalex
Cetadol
CHEBI:46195
Children'S acetaminophen elixir drops
Children'S acetaminophen oral solution
Children'S tylenol chewable
Claradol codeine
Clixodyne
Codabrol
COD-Acamol forte
Codalgin
Codapane
Codicet
Codisal
Codisal forte
Codoliprane
Codral pain relief
Cofamol
Co-Gesic
CO-Gesic
Conacetol
Contac cough & sore throat formula
Contra-schmerz P
Coricidin
Coricidin D
Coricidin sinus
Cosutone
Croix blanche
Cuponol
Curadon
Curpol
Custodial
D oliprane
Dafalgan
Dapa
Dapa X-S
Darocet
Darvocet
Darvocet-N 50
Datril
Datril extra-strength
Daygrip
Demilets
Deminofen
Democyl
Demogripal
Desfebre
Dhamol
DHC Plus
Dial-a-gesic
Dial-alpha-gesic
Dimindol
Dirox
Disprol
Dolcor
Dolefin
Dolegrippin
Dolene ap-65
Dolene AP-65
Dolgesic
Doliprane
Dolko
Dolofugin
Doloreduct
Dolorfug
Dolorol forte
Dolorstop
Dolotec
Dolprone
Dol-stop
Dorocoff
Dresan
Dristan cold no drowsiness
Dristancito
Drixoral Plus
Duaneo
Dularin
Duorol
Duracetamol
Duradyne DHC
Durapan
Dymadon
Dymadon co
Dymadon Co
Dymadon forte
Dypap
Ecosetol
Elixodyne
Empracet
Endecon
Enelfa
Eneril
Esgic
Esgic-plus
Eu-med
Eu-Med
Excedrin
Excedrin caplets
Excedrin extra strength caplets
Excipain
Exdol
Exdol strong
Fanalgic
Farmadol
Febranine
Febrectal
Febrectol
Febrex
Febricet
Febridol
Febrilix
Febrin
Febrinol
febro-Gesic
Febro-Gesic
Febrolin
Femcet
Fendon
Fensum
Fepanil
Fever All
Feverall
Feverall junior strength
Feverall sprinkle caps junior strength
Fevor
Finimal
Finiweh
Fioricet
Fluparmol
Fortalidon P
Freka-cetamol
Gattaphen T
Gelocatil
Geluprane
Genapap
Genapap children's elixir
Genapap children's tablets
Genapap extra strength caplets
Genapap extra strength tablets
Genapap regular strength tablets
Genebs
Genebs extra strength caplets
Genebs regular strength tablets
Genebs X-tra
Geralgine-P
Gripin bebe
Gripin Bebe
Grippostad
Gynospasmine
Hedex
Helon N
Homoolan
Hycomine compound
Hydrocet
Hy-phen
Hy-Phen
Ildamol
Inalgex
Infadrops
Infants' feverall
Influbene N
Injectapap
Intensin
Janupap
Jin Gang
Junior disprol
Kataprin
KBio1_000660
Kinder finimal
Korum
Kratofin simplex
L024125
Labamol
Lekadol
Lemgrip
Lemsip
Lestemp
Liqiprine
Liquagesic
Liquigesic co
Liquiprin
Liquiprin children's elixir
Liquiprin infants" drops
Lonarid
Lonarid mono
Lonarid Mono
Lorcet-HD
Lortab
Lupocet
Lyteca
Lyteca syrup
Lyteca Syrup
Magnidol
Malex N
Malgis
Malidens
Maxadol
Medigesic plus
Medinol paediatric
Medocodene
Melabon infantil
Mexalen
Midol maximum strength
Midol PM night time formula
Midol regular strength
Midol teen formula
Migraleve yellow
Minafen
Minoset
Miralgin
|
Momentum
mono Praecimed
Multin
N-(4-Hydroxyphenyl)acetamide
N-Acetyl-4-aminophenol
N-acetyl-p-aminophenol
N-Acetyl-P-aminophenol
Naldegesic
NAPA
Napafen
Napap
Naprinol
NCX 701
Nealgyl
Nebs
NEBS
NeoCitran
Neodol
Neodolito
neo-Fepramol
Neo-Fepramol
Neopap
Neotrend
Neuridon
New cortal for children
NilnOcen
Nina
Nobedon
Nodolex
NO-Febril
Noral
Norcet
Norco
NSC3991
O-Acetaminophenol
Ofirmev
Oltyl
Oralgan
Oraphen-PD
Ortensan
Oxycet
Oxycocet
Oxycodone 2.5/apap 500
Oxycodone 5/apap 500
P-(acetylamino)Phenol
Paceco
Pacemo
Pacemol
Pacet
p-acetamidophenol
P-Acetamidophenol
p-acetaminophenol
P-Acetaminophenol
p-Acetylaminophenol
P-Acetylaminophenol
Pacimol
Paedialgon
Paedol
Painex
Paldesic
Pamol
Panacete
Panadeine
Panadeine co
Panadeine Co
Panadiene
panado-Co
Panado-Co
panado-co Caplets
Panadol
Panadol extra strength
Panadol junior strength caplets
Panadol maximum strength caplets
Panadol maximum strength tablets
Panale ve
Panaleve
Panamax
Panasorb
Panasorbe
Panets
Panex
Panodil
Panofen
Pantalgin
Papa-Deine
Papa-deine #3
Papa-deine #4
Paracemol
Paracenol
Paracet
Paracetamol
Paracétamol
Paracetamol al
Paracetamol antipanin P
Paracetamol basics
Paracetamol BC
Paracetamol DC
Paracetamol dr. schmidgall
Paracetamol fecofar
Paracetamol genericon
Paracetamol hanseler
Paracetamol harkley
Paracetamol heumann
Paracetamol hexal
Paracetamol italfarmaco
Paracetamol nycomed
Paracetamol PB
Paracetamol raffo
Paracetamol ratiopharm
Paracetamol rosch
Paracetamol saar
Paracetamol smithkline beecham
Paracetamol stada
Paracetamol von CT
Paracetamol winthrop
Paracetamole
Paracetamolo
Paracetamolum
Paracetanol
Paracetol
Paracin
Paracod
Paracodol
Parador
Paradrops
Parakapton
Parake
Paralen
Paralief
Paralink
Paralyoc
Paramol
Paramolan
Paranox
Parapan
Parasedol
Parasin
Paraspen
Para-suppo
Para-Suppo
Para-tabs
Parcetol
Parelan
Parmol
Parogal
Paroma
Pasolind
Pasolind N
PCM Paracetamol lichtenstein
Pediapirin
Pediatrix
Pedric
Percocet
Percocet-5
Percocet-demi
Percogesic with codeine
Perdolan mono
Perfalgan
Pe-tam
Pe-Tam
Phenaphen
Phenaphen caplets
Phenaphen Caplets
Phenaphen w/codeine
Phendon
Phenipirin
Phogoglandin
Phrenilin
Phrenilin forte
Phrenilin Forte
p-hydroxy-acetanilid
p-hydroxyacetanilide
P-Hydroxyacetanilide
p-hydroxyphenolacetamide
P-Hydroxyphenolacetamide
Pinex
Piramin
Pirinasol
Plicet
Polmofen
Predimol
Predualito
Prestwick_13
Prodol
Prompt
Prontina
Propacet
Propacet 100
Proval #3
Puernol
Pulmofen
Pyregesic-C
Pyrigesic
Pyrinazine
Pyromed
Quiet world
Redutemp
Reliv
Remedol
Rhinex D-lay tablets
Rivalgyl
Robigesic
Robitussin night relief
Rockamol plus
Rounox
Roxicet
Roxicet 5/500
Roxilox
RubieMol
Rubophen
Rupemol
Salzone
Sanicet
Sanicopyrine
Scanol
Scentalgyl
Scherzatabletten rezeptur 534
Schmerzex
Sedalito
Sedapap
Semolacin
Servigesic
Seskamol
Setakop
Setamol
Setol
Sifenol
Sinaspril
Sinedol
Sine-OFF sinus medicine caplets
Sinmol
Sinubid
SK-Apap
Snaplets-FR
Spalt fur die nacht
Spalt N
SPBio_002836
ST Joseph aspirin-free
ST Joseph aspirin-free for children
St. joseph cold tablets for children
St. joseph fever reducer
St. Joseph Fever Reducer
Stanback
Stopain
Sudafed severe cold formula
Sudafed sinus
Sunetheton
Supac
Supadol mono
Supofen
Suppap
Suppap-120
Suppap-325
Suppap-650
Supramol-m
Supramol-M
Synalgos-Dc-A
Synalgos-DC-a
Tabalgin
Tachiprina
Talacen
Tapanol
Tapanol extra strength caplets
Tapanol extra strength tablets
Tapar
Tavist allergy/sinus/headache
Tavist Allergy/Sinus/Headache
Tazamol
Temlo
Tempanal
Tempra
Tempra caplets
Tempra chewable tablets
Tempra d.s
Tempra drops
Tempra syrup
Tencon
Termacet
Termalgin
Termalgine
Termofren
TheraFlu
Tibinide
Tibizide
Tiffy
Tisin
Tisiodrazida
Titralgan
Tizide
Tocris-1706
Toximer P
Tralgon
Treupel mon
Treupel N
Treuphadol
Triad
Triaminic sore throat formula
Triaprin
Tricoton
Tussapap
Ty lenol
Tycolet
TYL
Tylenol
Tylenol (TN)
Tylenol allergy sinus
Tylenol arthritis extended relief
Tylenol caplets
Tylenol children's chewable tablets
Tylenol children's elixir
Tylenol children's suspension liquid
Tylenol drops
Tylenol elixir
Tylenol extra strength adult liquid pain reliever
Tylenol extra strength caplets
Tylenol extra strength gelcaps
Tylenol extra strength tablets
Tylenol gelcaps
Tylenol infants drops
Tylenol infants" suspension drops
Tylenol junior strength caplets
Tylenol junior strength chewable tablets
Tylenol regular strength caplets
Tylenol regular strength tablets
Tylenol tablets
Tylex
Tylex CD
Tylol
Tylox
Tylox-325
Tymol
Ultracet
Upsanol
Utragin
Valadol
Valgesic
Valorin
Valorin extra
Valorin Extra
Vanquish
Veralgina
Vermidon
Verpol
Viclor richet
Vicodin
Vicodin es
Vicodin HP
Vips
Viruflu
Vivimed
Volpan
Wygesic
Zatinol
Zolben
|
|
| 16 |
|
Oxaliplatin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 17 |
|
leucovorin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
58-05-9 |
143
6006
|
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
Acid, folinic
Acide folinique
Acido folinico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
| 18 |
|
Capecitabine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
154361-50-9 |
60953
|
|
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
Capecitabin
capecitabina
Capecitabina
capecitabine
Capecitabine
CAPECITABINE
Capécitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
capecitabinum
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
CHEBI:31348
CHEMBL1773
CID60953
|
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
R340
R-340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
|
|
| 19 |
|
Irinotecan |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
100286-90-6, 97682-44-5 |
60838
|
|
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
7-Ethyl-10-hydroxycamptothecin
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
CP0
CPT 11
CPT-11
D08086
DB00762
|
FT-0083650
HSDB 7607
Irinophore C
irinotecan
Irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
LS-44589
NCI60_005051
NK012 Compound
NSC728073
S1198_Selleck
sn 38
sn-38
sn38 CPD
TL8006026
UNII-7673326042
|
|
| 20 |
|
Levoleucovorin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
68538-85-2 |
|
|
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-formyltetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
ácido levofolínico
|
Citrovorum factor
Levofolene
Levofolinic acid
L-Folinic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
|
|
| 21 |
|
Fluorouracil |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
51-21-8 |
3385
|
|
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
fluoro Uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
Fluorouracile [DCIT]
|
Fluorouracile dakota
Fluorouracile Dakota
fluoro-Uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
fluorouracilo Ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
haemato Brand OF fluorouracil
Haemato Brand of Fluorouracil
haemato Fu
Haemato fu
haemato-Fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
| 22 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4,Not Applicable |
|
2078-54-8 |
4943
|
|
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-bis(1-methylethyl)phenol
2,6-bis(1-methylethyl)-phenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-DIISOPROPYLPHENOL
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
Abbott brand OF propofol
Abbott Brand of Propofol
AC1L1J9Y
AC1Q1OUI
AC-2038
AI3-26295
Alpha Brand of Propofol
Alpha Brand OF propofol
AM-149
Ampofol
Aquafol
Astra brand OF propofol
Astra Brand of Propofol
AstraZeneca brand OF propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
Braun brand OF propofol
Braun Brand of Propofol
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD000059151
CPD-11437
Curamed brand OF propofol
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius brand OF propofol
Fresenius Brand of Propofol
Fresenius kabi brand OF propofol
Fresenius Kabi Brand of Propofol
Fresofol
ghl.PD_Mitscher_leg0.558
HMS1570L04
HMS2089O21
HMS2094E17
HSDB 7123
|
ICI 35,868
ICI 35868
ICI35,868
ICI-35,868
ICI35868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste brand OF propofol
Juste Brand of Propofol
Lopac0_000437
Lopac-D126608
LS-996
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
nchembio.552-comp7
NSC 5105
NSC5105
Parnell brand OF propofol
Parnell Brand of Propofol
PFL
Pisa brand OF propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol abbott
Propofol Abbott
Propofol fresenius
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol rovi
Propofol Rovi
Propofol(2,6-Diisopropylphenol)
Propofol-lipuro
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi brand OF propofol
Rovi Brand of Propofol
S01-0189
SAM002264610
Schering brand OF propofol
Schering Brand of Propofol
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
Zeneca brand OF propofol
Zeneca Brand of Propofol
ZINC00968303
|
|
| 23 |
|
Udenafil |
Approved, Investigational |
Phase 4,Phase 2 |
|
268203-93-6 |
6918523
|
|
Synonyms:
3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one
AC1OCFJA
CID6918523
DA 8159
DA-8159
|
DA-8159udenafil
DB06267
I14-12963
Udenafil
Zidena
Zydena
|
|
| 24 |
|
Sodium Citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
|
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
| 25 |
|
Dexmedetomidine |
Approved, Vet_approved |
Phase 4 |
|
113775-47-6 |
5311068
68602
|
|
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole
113775-47-6
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
DEXMEDETOMIDINE
Dexmédétomidine
|
Dexmedetomidine (USAN/INN)
Dexmedetomidine hydrochloride
Dexmedetomidinum
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
MPV 1440
MPV-1440
NCGC00025347-01
Precedex
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
|
|
| 26 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 4 |
|
209810-58-2, 11096-26-7 |
|
|
Synonyms:
Darbepoetin
Darbepoetin alfa,recombinant
|
|
|
| 27 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 4 |
|
28523-86-6 |
5206
|
|
Synonyms:
1,1,1,3,3,3-hexafluoro-2-(Fluoromethoxy)propane
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
Bax 3084
BRN 2041023
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
fluoromethyl hexafluoroisopropyl ether
Fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
|
LS-67851
MolPort-001-775-746
MR_6S4
MR6S4
NCGC00167421-01
PC4681
Sevofluran
sevoflurane
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
Ultane
Ultane (TN)
UNII-38LVP0K73A
ZINC01530810
|
|
| 28 |
|
Calcium |
Approved, Nutraceutical |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
7440-70-2 |
271
|
|
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
| 29 |
|
Citric Acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311
|
|
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
| 30 |
|
Analgesics, Non-Narcotic |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 31 |
|
Anesthetics, General |
|
Phase 4,Phase 3,Not Applicable |
|
|
|
| 32 |
|
Antirheumatic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 33 |
|
Acetaminophen, hydrocodone drug combination |
|
Phase 4 |
|
|
|
| 34 |
|
Analgesics, Opioid |
|
Phase 4,Phase 3,Not Applicable |
|
|
|
| 35 |
|
Anti-Anxiety Agents |
|
Phase 4,Not Applicable |
|
|
|
| 36 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4,Phase 2 |
|
|
|
| 37 |
|
Excitatory Amino Acids |
|
Phase 4,Phase 2 |
|
|
|
| 38 |
|
Antipyretics |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 39 |
|
Muscarinic Antagonists |
|
Phase 4,Phase 3 |
|
|
|
| 40 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4,Phase 2 |
|
|
|
| 41 |
|
Anti-Inflammatory Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 42 |
|
Anesthetics, Dissociative |
|
Phase 4 |
|
|
|
| 43 |
|
Tranquilizing Agents |
|
Phase 4,Phase 1,Phase 2,Not Applicable |
|
|
|
| 44 |
|
Anesthetics |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 45 |
|
Peripheral Nervous System Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
| 46 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable |
|
|
|
| 47 |
|
Anti-Arrhythmia Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
| 48 |
|
Central Nervous System Depressants |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
|
|
| 49 |
|
Anesthetics, Local |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
|
|
| 50 |
|
Cholinergic Antagonists |
|
Phase 4,Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 1541)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery |
Unknown status |
NCT02958566
|
Phase 4 |
Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET |
| 2 |
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer |
Unknown status |
NCT00274885
|
Phase 4 |
oxaliplatin |
| 3 |
Prospective Randomized Study of SILS Versus CLS for Rectal Cancer |
Completed |
NCT01579721
|
Phase 4 |
|
| 4 |
The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer |
Completed |
NCT01421940
|
Phase 4 |
Placebo drug;Udenafil |
| 5 |
Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer |
Completed |
NCT01912586
|
Phase 4 |
|
| 6 |
The Effect of Dexmedetomidine on Postoperative Analgesia |
Completed |
NCT01373021
|
Phase 4 |
Fentanyl;Dexmedetomidine |
| 7 |
The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery |
Completed |
NCT00122720
|
Phase 4 |
Darbepoetin Alfa |
| 8 |
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer |
Completed |
NCT00559676
|
Phase 4 |
capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin |
| 9 |
Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia |
Recruiting |
NCT01975064
|
Phase 4 |
Propofol;Sevoflurane |
| 10 |
Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL) |
Not yet recruiting |
NCT03083951
|
Phase 4 |
|
| 11 |
Radial Reload Laparoscopic LAR Case Series |
Terminated |
NCT01706822
|
Phase 4 |
|
| 12 |
Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma |
Terminated |
NCT00216424
|
Phase 4 |
Capecitabine (Xeloda) |
| 13 |
Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer |
Unknown status |
NCT02905968
|
Phase 2, Phase 3 |
|
| 14 |
Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer |
Unknown status |
NCT01308190
|
Phase 3 |
Capecitabine (Xeloda) |
| 15 |
Preoperative Radiotherapy and Local Excision in Rectal Cancer |
Unknown status |
NCT00738790
|
Phase 3 |
|
| 16 |
The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer |
Unknown status |
NCT00833131
|
Phase 3 |
|
| 17 |
Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer |
Unknown status |
NCT01224392
|
Phase 3 |
|
| 18 |
A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) |
Unknown status |
NCT00601549
|
Phase 3 |
|
| 19 |
Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer |
Unknown status |
NCT02964468
|
Phase 3 |
|
| 20 |
Randomized Trial on Robotic Assisted Resection for Rectal Cancer |
Unknown status |
NCT01130233
|
Phase 3 |
|
| 21 |
Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer |
Unknown status |
NCT00597311
|
Phase 3 |
|
| 22 |
A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer |
Unknown status |
NCT01064999
|
Phase 2, Phase 3 |
Oxaliplatin;Capecitabine |
| 23 |
Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer |
Unknown status |
NCT00470951
|
Phase 3 |
|
| 24 |
Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer. |
Unknown status |
NCT01814969
|
Phase 3 |
|
| 25 |
COLOR II: Laparoscopic Versus Open Rectal Cancer Removal |
Unknown status |
NCT00297791
|
Phase 3 |
|
| 26 |
Resource-Sparing Curative Treatment for Rectal Cancer |
Unknown status |
NCT01459328
|
Phase 3 |
|
| 27 |
A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer |
Unknown status |
NCT01423214
|
Phase 3 |
|
| 28 |
Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer |
Unknown status |
NCT00007930
|
Phase 3 |
|
| 29 |
Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer |
Unknown status |
NCT00154752
|
Phase 3 |
|
| 30 |
Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer |
Unknown status |
NCT00227747
|
Phase 3 |
capecitabine;oxaliplatin |
| 31 |
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer |
Unknown status |
NCT00058474
|
Phase 3 |
capecitabine;fluorouracil;oxaliplatin |
| 32 |
Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer |
Unknown status |
NCT02770911
|
Phase 3 |
|
| 33 |
Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery |
Unknown status |
NCT02576184
|
Phase 3 |
|
| 34 |
Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study |
Unknown status |
NCT01653301
|
Phase 3 |
XELAC RT;XELOX RT |
| 35 |
Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer |
Unknown status |
NCT00002896
|
Phase 3 |
chemotherapy;fluorouracil;leucovorin calcium |
| 36 |
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer |
Unknown status |
NCT00189657
|
Phase 3 |
|
| 37 |
Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Anterior Resection |
Unknown status |
NCT01861678
|
Phase 3 |
|
| 38 |
VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer |
Unknown status |
NCT01579591
|
Phase 3 |
|
| 39 |
A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment. |
Unknown status |
NCT01941979
|
Phase 3 |
5-FU, Capecitabine, Oxaliplatin, Leucovorin. |
| 40 |
β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence |
Unknown status |
NCT00888797
|
Phase 3 |
Propranolol and Etodolac |
| 41 |
J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma |
Unknown status |
NCT00070005
|
Phase 3 |
|
| 42 |
Monitoring by Microdialysis of Postoperative Complications After Proctectomy |
Unknown status |
NCT01999634
|
Phase 3 |
|
| 43 |
Increasing Colorectal Cancer Screening in African Americans |
Unknown status |
NCT00893295
|
Phase 3 |
|
| 44 |
Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants |
Unknown status |
NCT00617071
|
Phase 3 |
|
| 45 |
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. |
Unknown status |
NCT00337389
|
Phase 3 |
5- Fluorouracil (5-FU);bevacizumab (Avastin);Leucovorin;CoFactor (ANX-510) |
| 46 |
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
Unknown status |
NCT00797485
|
Phase 3 |
capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium |
| 47 |
Electroacupuncture Versus Fast-track Perioperative Program for Laparoscopic Colorectal Surgery |
Unknown status |
NCT02059603
|
Phase 3 |
|
| 48 |
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium |
Unknown status |
NCT02928692
|
Phase 3 |
Minocycline;Placebo |
| 49 |
Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer |
Unknown status |
NCT00003063
|
Phase 3 |
fluorouracil;leucovorin calcium;levamisole hydrochloride |
| 50 |
ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. |
Unknown status |
NCT01589146
|
Phase 3 |
Heparin, Low-Molecular-Weight |
Cochrane evidence based reviews: rectal neoplasms
|
